74 related articles for article (PubMed ID: 7755609)
1. An age-related correlation between levels of beta-amyloid precursor protein and beta-amyloid in human cerebrospinal fluid.
Carroll RT; Lust MR; Kim KS; Doyle PD; Emmerling MR
Biochem Biophys Res Commun; 1995 May; 210(2):345-9. PubMed ID: 7755609
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
3. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.
Nakamura T; Shoji M; Harigaya Y; Watanabe M; Hosoda K; Cheung TT; Shaffer LM; Golde TE; Younkin LH; Younkin SG
Ann Neurol; 1994 Dec; 36(6):903-11. PubMed ID: 7998778
[TBL] [Abstract][Full Text] [Related]
4. Lower levels of cerebrospinal fluid amyloid beta (Abeta) in non-demented Indian controls.
Subramanian S; Sandhyarani B; Shree AN; Murthy KK; Kalyani K; Kumar SP; Pradeep ; Noone MJ; Taly AB
Neurosci Lett; 2006 Oct; 407(2):121-3. PubMed ID: 16978775
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina.
Löffler KU; Edward DP; Tso MO
Invest Ophthalmol Vis Sci; 1995 Jan; 36(1):24-31. PubMed ID: 7822152
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls.
Peskind ER; Leverenz J; Farlow MR; Ito RK; Provow SA; Siegel RS; Cleveland M; Morgan CH; Pandian MR; Corbin S; Nochlin D; Schellenberg GD; Raskind MA; Wagner SL
Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):201-6. PubMed ID: 9437437
[TBL] [Abstract][Full Text] [Related]
8. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.
Peskind ER; Li G; Shofer J; Quinn JF; Kaye JA; Clark CM; Farlow MR; DeCarli C; Raskind MA; Schellenberg GD; Lee VM; Galasko DR
Arch Neurol; 2006 Jul; 63(7):936-9. PubMed ID: 16831961
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice.
Liu L; Herukka SK; Minkeviciene R; van Groen T; Tanila H
Neurobiol Dis; 2004 Dec; 17(3):516-23. PubMed ID: 15571987
[TBL] [Abstract][Full Text] [Related]
11. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse.
Lehman EJ; Kulnane LS; Gao Y; Petriello MC; Pimpis KM; Younkin L; Dolios G; Wang R; Younkin SG; Lamb BT
Hum Mol Genet; 2003 Nov; 12(22):2949-56. PubMed ID: 14506131
[TBL] [Abstract][Full Text] [Related]
12. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
[TBL] [Abstract][Full Text] [Related]
13. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.
de Bont JM; Vanderstichele H; Reddingius RE; Pieters R; van Gool SW
Eur J Paediatr Neurol; 2008 Jul; 12(4):334-41. PubMed ID: 17951083
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
15. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
Mattsson N; Axelsson M; Haghighi S; Malmeström C; Wu G; Anckarsäter R; Sankaranarayanan S; Andreasson U; Fredrikson S; Gundersen A; Johnsen L; Fladby T; Tarkowski A; Trysberg E; Wallin A; Anckarsäter H; Lycke J; Andersen O; Simon AJ; Blennow K; Zetterberg H
Mult Scler; 2009 Apr; 15(4):448-54. PubMed ID: 19153172
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
17. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
Zhong Z; Ewers M; Teipel S; Bürger K; Wallin A; Blennow K; He P; McAllister C; Hampel H; Shen Y
Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753
[TBL] [Abstract][Full Text] [Related]
18. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
19. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
[TBL] [Abstract][Full Text] [Related]
20. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.
Sankaranarayanan S; Holahan MA; Colussi D; Crouthamel MC; Devanarayan V; Ellis J; Espeseth A; Gates AT; Graham SL; Gregro AR; Hazuda D; Hochman JH; Holloway K; Jin L; Kahana J; Lai MT; Lineberger J; McGaughey G; Moore KP; Nantermet P; Pietrak B; Price EA; Rajapakse H; Stauffer S; Steinbeiser MA; Seabrook G; Selnick HG; Shi XP; Stanton MG; Swestock J; Tugusheva K; Tyler KX; Vacca JP; Wong J; Wu G; Xu M; Cook JJ; Simon AJ
J Pharmacol Exp Ther; 2009 Jan; 328(1):131-40. PubMed ID: 18854490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
